← Back to Clinical Trials
Recruiting NCT05028309

NCT05028309 Effects of Obesity in the Aged

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05028309
Status Recruiting
Phase
Sponsor University of Texas Southwestern Medical Center
Condition Obesity
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2021-12-01
Primary Completion 2026-08-31

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age 75 Years
Study Type INTERVENTIONAL
All Conditions
Interventions
Mechanical unloading of the Thorax using an external cuirass

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 72 participants in total. It began in 2021-12-01 with a primary completion date of 2026-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overall objective of this application is to investigate the effects of obesity on lung function, exercise tolerance, and DOE in older obese adults as compared with older adults without obesity, using a novel probe for mechanically unloading the thorax at rest and during exercise. The investigators will use 1) continuous negative cuirass pressure, and 2) assisted biphasic cuirass ventilation to decrease obesity-related effects in older obese adults. Our approach will be to examine respiratory function, exercise tolerance, and DOE with and without mechanical unloading in older obese men and women (65-75 yr), including those with respiratory symptoms (defined by a score of 1 or 2 on the modified Medical Research Council Dyspnea Scale), as compared with older adults without obesity. Specific Aims: The investigators will test the following hypotheses in older adults with and without obesity: Aim 1) Obesity will decrease respiratory function but to a greater extent in older obese adults with respiratory symptoms, (as evidenced by altered pulmonary function and breathing mechanics at rest); Aim 2) Obesity will decrease exercise tolerance (as evidenced by peak V•O2 in ml/min/kg, i.e., physical fitness), but not cardiorespiratory fitness (as evidenced by peak V•O2 in % of predicted based on ideal body wt), except in older obese adults with respiratory symptoms where both may be reduced during graded cycle ergometry. Aim 3) Obesity will increase DOE but to a greater extent in older obese adults with respiratory symptoms as evidenced by increased ratings of perceived breathlessness (sensory \& affective dimensions) during exercise. Aim 4) Mechanical unloading of the thorax will improve respiratory function, submaximal exercise tolerance, and DOE in older obese adults, but to a greater extent in older obese adults with respiratory symptoms.

Eligibility Criteria

Inclusion Criteria: * Otherwise healthy older adults 65-75 years of age with normal lung function; men 30\< %body fat ≤50 and women 35\< %body fat ≤55; and ability to perform pulmonary and exercise test. Other inclusion criteria include the following: * Nonsmokers who have no history of smoking * No personal history of significant mental illness * No weight loss dietary restrictions * No current or past history of significant substance or alcohol abuse * No history, evidence, or uncontrolled symptoms of heart disease * No history of uncontrolled hypertension * No current medications that may interfere with exercise capacity * No recent history or indication of asthma * No musculoskeletal abnormality that would preclude exercise * No serious health conditions that would preclude study goals or participation in exercise (per PI \& medical staff \& preliminary or follow up testing; including significant other diseases, occult asthma, prior surgeries-especial lung or abdominal, or history of chemotherapy that could affect lung or heart function) * Only postmenopausal women will be included. * Women on hormone replacement therapy will be allowed to participate if the dosage remains similar during the entire protocol. Exclusion Criteria: * Volunteers with a mMRC score of 3 or 4 will be excluded due to likeliness of underlying disease. * Individuals participating in regular vigorous conditioning exercise such as running, jogging, aerobics, cycling, or swimming more than three times per week will be excluded. However, if subjects have an exceedingly high exercise capacity (greater than 2 SD of predicted), they will be excluded. * Maximal cycle ergometry test will be used to determine if further participation in testing is appropriate for the participant (e.g., normal exercise test, exclude presence of provokable ECG changes suggestive of heart disease, or dangerous arrhythmias or exercise induced hypertension or bronchoconstriction. If the participant develops an abnormal ECG or shows other signs of exercise intolerance or if signs of cardiovascular disease are noted during the exercise test, it will be terminated and the participant will be referred to their personal physician for further evaluation (see DMSP). * Premenopausal women will be excluded.

Contact & Investigator

Central Contact

Research Nurse

✉ IEEMLung@TexasHealth.org

📞 214-345-6574

Principal Investigator

Tony G Babb, Ph.D.

PRINCIPAL INVESTIGATOR

University of Texas Southwestern Medical Center

Frequently Asked Questions

Who can join the NCT05028309 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, up to 75 Years, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05028309 currently recruiting?

Yes, NCT05028309 is actively recruiting participants. Contact the research team at IEEMLung@TexasHealth.org for enrollment information.

Where is the NCT05028309 trial being conducted?

This trial is being conducted at Dallas, United States.

Who is sponsoring the NCT05028309 clinical trial?

NCT05028309 is sponsored by University of Texas Southwestern Medical Center. The principal investigator is Tony G Babb, Ph.D. at University of Texas Southwestern Medical Center. The trial plans to enroll 72 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology